Use for the qualitative detection of IgG antibodies against the nucleocapsid protein of SARS-CoV-2 (COVID-19) that develop in response to natural infection with SARS-CoV-2. These antibodies do not develop as a result of a COVID-19 vaccination. There are no current recommendations for assessing COVID-19 vaccine response.
To reduce the likelihood of a false-positive result, the CDC Interim Guidelines for COVID-19 Antibody Testing suggest using an orthogonal testing algorithm so that individuals positive by one antibody test are retested with a second antibody test (refer to COVID-19 IgG by ELISA 3002723).
Qualitative Chemiluminescent Immunoassay
New York DOH Approval Status
Serum separator tube (SST) or EDTA plasma
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 0.5mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.25 mL)
Grossly hemolyzed, grossly icteric, or severely lipemic specimens.
Preferred: ARUP Standard Transport Tube for specimen submission (ARUP Item# 15824).
Refrigerated: 1 week; Frozen: 1 month
The COVID-19 IgG, Qualitative by CIA test is for in vitro diagnostic use under an FDA Emergency Use Authorization (EUA). In compliance with this authorization, please visit https://www.aruplab.com/infectious-disease/coronavirus/testing for more information and to access the applicable information sheets. This test should not be used for screening of donated blood.
Emergency Use Authorization (EUA)
|Component Test Code*||Component Chart Name||LOINC|
|3002777||COVID-19 IgG, Qualitative||94507-1|
- Coronavirus Disease - 2019
- COVID-19 Illness
- COVID19 IgG Ab